Insider trades
Shelley B. Thunen, Director of Aeon Biopharma AEON, has filed 0 purchases and 26 sales on the open market. The latest trade was on 06/17.
Shelley B. Thunen
Director
- Company
- Aeon Biopharma AEON
- First filing
- 23/03/10
- Trades
- 67 trades
- Buys / sales
- 0 / 26
- 12-month net buying
- No record
- Last trade
- 06/17
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
RXST | Open-market sale10b5-1 plan | 24/10/01 | 24/10/02 | 15,000 sh3 trades | $48.45avg. | $726,764.55 | −33.0% |
RXST | Open-market sale10b5-1 plan | 24/07/01 | 24/07/02 | 18,402 sh4 trades | $58.68avg. | $1,079,841.91 | No record |
RXST | Open-market sale10b5-1 plan | 24/05/01 | 24/05/02 | 10,000 sh2 trades | $52.69avg. | $526,936.8 | −41.8% |
RXST | Open-market sale10b5-1 plan | 24/04/01 | 24/04/02 | 20,000 sh6 trades | $49.89avg. | $997,882.33 | −70.4% |
RXST | Open-market sale10b5-1 plan | 24/03/01 | 24/03/05 | 10,000 sh3 trades | $56.37avg. | $563,740.07 | −42.2% |
RXST | Open-market sale | 24/02/05–24/02/06 | 24/02/07 | 25,000 sh2 trades | $47.31avg. | $1,182,643.75 | −64.6% |
RxSightRXST | Open-market sale | 24/01/26 | 24/01/29 | 31,772 sh | $47.11 | $1,496,778.92 | −82.4% |
RXST | Open-market sale10b5-1 plan | 24/01/02 | 24/01/03 | 10,000 sh2 trades | $39.24avg. | $392,413.66 | −81.4% |
RXST | Open-market sale10b5-1 plan | 23/12/15 | 23/12/18 | 40,000 sh3 trades | $39.33avg. | $1,573,300 | No record |
